There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Inozyme Pharma Inc. (INZY) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.08, or 1.87%, to $4.36. The Inozyme Pharma Inc. has recorded 12,401 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $4.28 and fluctuated between $4.7200 as its day high and $4.2725 as its day low. The current market capitalization of Inozyme Pharma Inc. is $268.61M. A total of 1.02 million shares were traded on the day, compared to an average of 652.09K shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, INZY has seen 4 BUY and 0 SELL insider trades, representing the acquisition of 1,666,666 and the disposition of 0 shares. Over the last 12 months, there were 13 BUYs and 0 SELLs from insiders. Insiders purchased 2,481,715 shares during that period but sold 0.
In the most recent transaction, Hopfner Robert Lorne bought 833,333 shares of INZY for 4.80 per share on Aug 01. After the transaction, the Director now owns 2,923,110 company shares. In a previous transaction on Aug 01, Pivotal bioVenture Partners Fu bought 833,333 shares at 4.80 per share. INZY shares that Director owns now total 2,923,110.
Among the insiders who bought shares, Hopfner Robert Lorne acquired of 228,702 shares on May 12 at a per-share price of $6.25. This resulted in the Director holding 3,661,518 shares of INZY after the transaction. In another insider transaction, Hopfner Robert Lorne bought 219,230 shares at $6.48 per share on May 11. Company shares held by the Director now total 3,432,816.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for INZY in the last 3 months, the mean price target is $20.33 with high estimates of $40.00 and low estimates of $12.00. In terms of 52-week highs and lows, INZY has a high of $7.33 and a low of $0.99.
As of this writing, INZY has an earnings estimate of -$0.32 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.28 per share and a lower estimate of -$0.36. The company reported an EPS of -$0.4 in the last quarter, which was 11.10% higher than expectations of -$0.45.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. INZY’s latest balance sheet shows that the firm has $111.80M in Cash & Short Term Investments as of fiscal 2021. There were $3.37M in debt and $11.63M in liabilities at the time. Its Book Value Per Share was $2.35, while its Total Shareholder’s Equity was $109.27M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for INZY is Buy with a score of 4.86.